"
Team:MIT
From 2014.igem.org
(Difference between revisions)
| Line 18: | Line 18: | ||
<table width=95% align=center> | <table width=95% align=center> | ||
<tr><td><h3 style="font-size:20px" align=center>Improving the Diagnosis and Treatment of</h3></td></tr> | <tr><td><h3 style="font-size:20px" align=center>Improving the Diagnosis and Treatment of</h3></td></tr> | ||
| - | <tr><td><h3 style="font-size: | + | <tr><td><h3 style="font-size:50px" align=center>ALZHEIMER'S DISEASE</h3></td></tr> |
<tr><td><h3 style="font-size:25px" align=right></h3></td></tr> | <tr><td><h3 style="font-size:25px" align=right></h3></td></tr> | ||
| Line 30: | Line 30: | ||
<table width=95% align=center> | <table width=95% align=center> | ||
| - | <tr><td><p align=left>Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by memory loss, behavioral problems… There is currently no cure for this disease, and existing diagnosis methods leave much to be desired. MIT iGEM 2014 has set out to change this. By detecting molecular biomarkers for AD, such as miRNAs and neurotoxic beta-amyloid plaques, and by regulating the production of beta-amyloid plaques, MIT iGEM hopes to create a dynamic solution for patients with Alzheimer’s disease. Looking ahead, … delivery.< | + | <tr><td><p align=left>Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by memory loss, behavioral problems… There is currently no cure for this disease, and existing diagnosis methods leave much to be desired. MIT iGEM 2014 has set out to change this. By detecting molecular biomarkers for AD, such as miRNAs and neurotoxic beta-amyloid plaques, and by regulating the production of beta-amyloid plaques, MIT iGEM hopes to create a dynamic solution for patients with Alzheimer’s disease. Looking ahead, … delivery.</p></td></tr> |
| - | + | <tr><td><h3 style="font-size:35px" align=center><u>DETECTION → TREATMENT → DELIVERY</u></h3></td></tr> | |
| + | <tr><td><br></td></tr> | ||
</table> | </table> | ||
| Line 38: | Line 39: | ||
</tr> | </tr> | ||
<tr> | <tr> | ||
| - | <td width=33.3%><img src="https://static.igem.org/mediawiki/2014/e/e9/MIT_Native_receptor_homepage.png"><br> | + | <td width=33.3%><img src="https://static.igem.org/mediawiki/2014/e/e9/MIT_Native_receptor_homepage.png"><br><p style="font-size:15px">Native beta-amyloid receptor</p></td> |
| - | <td width=33.3%><img src="https://static.igem.org/mediawiki/2014/f/f8/MIT_bcr_homepage.png"><br>Engineered | + | <td width=33.3%><img src="https://static.igem.org/mediawiki/2014/f/f8/MIT_bcr_homepage.png"><br><p style="font-size:15px">Engineered B-cell receptor</p></td> |
| - | <td width=33.3%><img src="https://static.igem.org/mediawiki/2014/8/88/MIT_mirna_homepage.png"><br> | + | <td width=33.3%><img src="https://static.igem.org/mediawiki/2014/8/88/MIT_mirna_homepage.png"><br><p style="font-size:15px">miRNA sensors for Alzheimer’s state</p></td> |
<tr> | <tr> | ||
</table> | </table> | ||
| Line 52: | Line 53: | ||
<td width=50%><img src="https://static.igem.org/mediawiki/2014/0/06/MIT_future_homepage.png"></td> | <td width=50%><img src="https://static.igem.org/mediawiki/2014/0/06/MIT_future_homepage.png"></td> | ||
</tr> | </tr> | ||
| - | <tr><td> | + | <tr><td><p style="font-size:15px">Regulating beta-amyloid production<br> and degradation</p></td> |
| - | <td> | + | <td><p style="font-size:15px">Delivering our circuit</p> </td> |
</tr> | </tr> | ||
</table> | </table> | ||
Revision as of 06:34, 15 October 2014
| Home |  Our Project
|
Lab Work
|
Outreach
|
About Us
|
Medals |
Improving the Diagnosis and Treatment of | ||
ALZHEIMER'S DISEASE | ||
| [Dying Neuron] Neurodegenerative Disease |
[6th] Leading cause of death in the US |
[Vaccine] Current diagnosis and therapeutics are not effective |
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by memory loss, behavioral problems… There is currently no cure for this disease, and existing diagnosis methods leave much to be desired. MIT iGEM 2014 has set out to change this. By detecting molecular biomarkers for AD, such as miRNAs and neurotoxic beta-amyloid plaques, and by regulating the production of beta-amyloid plaques, MIT iGEM hopes to create a dynamic solution for patients with Alzheimer’s disease. Looking ahead, … delivery. |
DETECTION → TREATMENT → DELIVERY |
DETECTION |
||
 Native beta-amyloid receptor |
 Engineered B-cell receptor |
 miRNA sensors for Alzheimer’s state |
TREATMENT |
DELIVERY |
 |
 |
Regulating beta-amyloid production |
Delivering our circuit |
